BR Biomedical Reports 2049-9434 2049-9442 D.A. Spandidos 10.3892/br.2015.428 BR-0-0-428 Articles Volatile anesthetic sevoflurane ameliorates endotoxin-induced acute lung injury via microRNA modulation in rats OTSUKITATSURO ISHIKAWAMASASHI HORIYOKO GOTOGENTARO SAKAMOTOATSUHIRO Department of Anaesthesiology and Pain Medicine Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo 113-8603, Japan Correspondence to: Mr. Tatsuro Otsuki, Department of Anaesthesiology and Pain Medicine Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan, E-mail: truant7140@nms.ac.jp 2015-05-01 2015-02-12 3 3 408 412 11122014 29012015 Copyright © 2015, Spandidos Publications 2015

Volatile anesthetics have a lung protective effect in acute lung injury (ALI). Our previous study showed sevoflurane affects the expression of microRNA (miRNA) that control various physiological systems by regulating messenger RNA (mRNA) expression. However, the association between the anti-inflammatory effect of sevoflurane and miRNAs modulation remains unknown. The aim of the present study was to investigate the effect of sevoflurane and the expression of miRNAs in an endotoxin-induced ALI model in rats. Wistar rats were randomly assigned to three groups [lipopolysaccharide (LPS), LPS-sevoflurane and control; n=8/group]. All the rats were mechanically ventilated and intravenously-administered LPS (saline as control). Two hours post-injury, general anaesthesia was performed for 4 h with 2% sevoflurane (LPS-sevoflurane). The LPS and the control groups did not receive anaesthesia. The severity of ALI was evaluated by partial pressure of oxygen/fraction of inspired oxygen and the mRNA expression of inflammatory cytokine. The miRNA expression in lung tissue was analyzed by a reverse transcription-quantitative polymerase chain reaction. LPS caused ALI, evidenced by the impairment of pulmonary function and increased mRNA levels of tumor necrosis factor-α, interleukin-6 and nuclear factor-κB. Sevoflurane improved pulmonary function and inhibited the increased mRNAs. Of the 219 miRNAs detected, 15 and nine miRNAs were significantly changed in the LPS and LPS-sevoflurane group, respectively. In the LPS-sevoflurane group, the expression of several miRNAs that regulate inflammation was significantly changed compared to the LPS group. In conclusion, the present data showed that sevoflurane influences the expression of the miRNAs that regulate inflammation. This result suggests that the changes in miRNA expression are involved in the lung protective mechanisms of volatile anesthetics.

 volatile anaesthetics sevoflurane microRNA acute lung injury postconditioning Introduction

Acute lung injury (ALI) is a major complication in critically ill patients (1). Therefore, it is important to preserve lung function and prevent further exacerbation for those patients whose lungs are already vulnerable prior to surgery. The volatile anesthetic sevoflurane is known to have organ protective effects in several pathological conditions. For example, Voigtsberger et al (2) have recently shown that sevoflurane ameliorates gas exchange and attenuates lung damage in a model of lipopolysaccharide (LPS)-induced ALI.

MicroRNA (miRNA) is a newly discovered and non-coding RNA that regulates genome expression at the post-transcriptional level (3). miRNA is estimated to control 30–90% of human genes (4). miRNA has been suggested to either suppress messenger RNA (mRNA) translation or reduce mRNA stability by binding particular regions of mRNA (5). Recent published data have also revealed that the expression and function of miRNA are associated with a broad range of diseases.

In our previous study, it was found that sevoflurane affects the expression of miRNAs in normal rat lung (6). However, such effects of anesthetic ALI remain unknown. Therefore, we hypothesized that sevoflurane affects the miRNAs that regulate inflammatory responses and investigated changes of miRNA in an LPS-induced ALI model in rats.

 Materials and methods <sec> <title>Approval

The study was approved by the Animal Research Committee of Nippon Medical School, Tokyo, Japan (approval no. 22–147).

 Sample preparation

Male Wistar rats (Tokyo Experimental Animals Supply, Tokyo, Japan) weighing 400±50 g were housed at 22±1˚C under a 12-h light/12-h dark cycle. The rats freely accessed food ad libitum and water. All the rats were anesthetized by intra-peritoneal injection of sodium pentobarbital (50 mg/kg) for the surgical procedure and subsequently maintained with hourly injections (15 mg kg−1) when necessary. The rats were placed supine on a heating blanket under a heating lamp to maintain a body temperature of 37˚C throughout the experiments. For continuous anesthetic infusion and fluid administration, the tail vein was cannulated with a sterile 24-gauge catheter and normal saline was administered via the catheter at a rate of 5 ml kg−1 h−1. A sterile 24-gauge polyethylene catheter was placed in the left femoral artery for blood sampling and blood pressure monitoring. All the rats were tracheotomized and a sterile 14-gauge catheter was inserted into the trachea, followed by mechanical ventilation (rodent ventilator model 638; Harvard Apparatus, Holliston, MA, USA) in the volume-controlled mode (8 ml kg−1 tidal volume) without positive end-expiratory pressure. The fraction of inspired oxygen (FiO2) concentration was 1.0. The inspiratory-expiratory ratio was 1:2 and respiratory frequency was 60–70 min−1.

The rats were randomly assigned to three different groups (n=8/group): i) Control, ii) LPS and iii) LPS-sevoflurane. Rats in the control and LPS groups were intravenously injected with 10 mg kg−1 Escherichia coli-LPS (serotype 055:B5; Sigma Aldrich, St. Louis, MO, USA) dissolved in 1 ml of normal saline. The control group received an equal volume of normal saline. The injection was defined as 0 time point. Two hours after the injection, the LPS-sevoflurane group received 2.0% sevoflurane (Maruishi Pharmaceutical, Co., Ltd., Osaka, Japan) for 4 h, but not the control and LPS group. At the end of the 6 h experimental period, arterial blood gas and mean arterial pressure (MAP) were measured and the arterial oxygen tension to inspired oxygen fraction [partial pressure of oxygen (PaO2)/FiO2] was calculated. Finally, all the rats were sacrificed by decapitation. The right lungs were obtained immediately and washed with phosphate-buffered saline and stored in RNAlater® (Life Technologies, Applied Biosystems, Carlsbad, CA, USA) at −80˚C until use.

 Quantification of miRNA and mRNA expression by reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

RT-qPCR was performed as described previously (7). Total RNA was isolated from the lung samples using a mirVana miRNA isolation kit® (Ambion, Life Technologies, Waltham, MA, USA) according to the manufacturer's instructions. RNA amounts and purity were assessed by absorbance at 260 nm and 260/280-nm ratio, respectively, with a NanoDrop ND-1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA). Samples with an A260/280-nm of ≥1.8 were qualified for qPCR.

Quantification of mature miRNA expression was performed using the TaqMan microRNA reverse transcription kit, TaqMan Universal PCR Mastermix, Megaplex Reverse Transcription primer Pool A/B and TLDA Rodent MicroRNA card A/B (Life Technologies, Applied Biosystems). Each card contains 373 preloaded rat miRNA targets, all catalogued in the miRNA database. Mann U6 was selected as an endogenous control. All procedures were performed according to manufacturer's protocols. Amplification and detection were performed using a 7900 HT real time PCR System (Life Technologies, Applied Biosystems). For quantification of miRNA expression, the comparative Ct method (ΔΔCt) was used. The target gene was quantified relative to the control gene and is expressed as fold change, calculated as 2−ΔΔCt.

For mRNA analysis, a High Capacity cDNA RT kit (Life Technologies, Applied Biosystems) and TaqMan mRNA assay primers for tumor necrosis factor-α (TNF-α, cat. no. 4331182), interleukin-6 (IL-6 cat. no. 4331182) and nuclear factor-κB (NF-κB, cat. no. 4351372) were used with 1 ng of total RNA/reaction. Reverse transcription was performed at 20˚C for 5 min, 42˚C for 30 min and 95˚C for 5 min on a GeneAmp® 5700 system (Life Technologies, Applied Biosystems). Quantification of mRNA expression was performed in the same manner following normalization to GAPDH and is expressed relative to the control group. The data analysis was performed using DataAssist software v2.0 (Life Technologies, Applied Biosystems).

 Statistical analysis

All the data are expressed as means ± standard deviation. For multiple group comparisons, analysis of variance followed by Tukey's test (P<0.05) was performed to compare the physiological data and the relative expression of mRNA. Tukey's test (P<0.01) was applied to identify miRNAs that were differentially expressed compared to the control group. Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA).

 Results <sec> <title>Physiological data

Arterial blood gas analysis showed that the rats administered LPS had a significant decrease in PaO2/FiO2 (FiO2=1.0) compared to the control 6 h post-injury. Among the two LPS groups, however, the LPS-sevoflurane group had significantly higher PaO2/FiO2 and lower PaCO2 compared to the LPS groups (Table I). The MAP in the two LPS groups was significantly lower than that of the control. There were no significant differences in MAP among the two LPS groups.

 Expression of miRNA

RT-qPCR analysis showed that 219 miRNAs out of 373 miRNAs examined were expressed. Relative expression ratios of miRNAs compared to the control group are presented in Table II. There were 23 differentially expressed miRNAs in the LPS group. In the LPS group, miR-155 and miR-146a showed marked increases; 19.36±4.47 and 7.32±2.01, respectively. Following sevoflurane anesthesia, miR-155 was significantly decreased (8.01±2.23) but miR-146 had no significant change (8.67±2.27) from LPS alone (Table II).

 Expression of mRNA

Compared to the control group, mRNA expression of TNF-α, IL-6 and NF-κB were significantly increased in the two groups treated with LPS. Compared to the LPS group, the expression of TNF-α, IL-6 and NF-κB mRNA decreased significantly in the LPS-sevoflurane group (Fig. 1).

 Discussion

The main finding of the present study was that sevoflurane anesthesia not only improves oxygenation and ameliorates inflammation, but also alters miRNA expression in an ALI rat model. Notably, some of the significantly expressed miRNAs in the study are known to regulate the innate immune system against inflammation induced by LPS per se. This system is triggered by the recognition of LPS by Toll-like receptor 4 (TLR4) and the signal activates intracellular signaling cascades that result in NF-κB activation and subsequent production of inflammatory cytokines, including TNF-α and IL-6 (8). Recent studies in macrophages, neutrophils, monocytes, epithelial cells and even whole lungs have shown that activation of TLR4 and TNF-α receptors results in rapid expression of miRNAs, including let-7, miR-9, miR-99b, miR-125a/b, miR-132, miR-146a, miR-155, miR-187 and miR-223 (9–12). Of these, let-7, miR-9, miR-125a, miR-146a and miR-155 were significantly upregulated by LPS as demonstrated in the study.

The present data showed that the expression of miR-155 is enhanced by LPS stimulation and sevoflurane had an ameliorating effect. This change parallels with the changes in the expression of inflammatory cytokine mRNAs. Tili et al (13) showed that mice overexpressing miR-155 in B-cells produced more TNF-α when challenged with LPS and the increase of TNF-α accelerated the onset of mortality. This finding established that the upregulation of miR-155 in response to LPS is an indicator of an increased sensitivity to endotoxin stimulation. Collectively, these results suggest that volatile anesthetics attenuate the toxic effect of LPS by affecting miR-155 expression. This finding highlights the importance of further investigation into whether blocking miR-155 can be used as therapeutic intervention to dampen excessive inflammation.

Several studies have indicated that miR-146a negatively regulates the activation of inflammatory pathways by controlling the TLR4 pathway through a negative-feedback mechanism (9). During the inflammatory response to microbial invasion, miR-146a is shown to increase continuously and remain at a high level, exerting negative feedback effects on several mRNAs of adaptor kinases downstream of TLR4 signal transduction. In this upregulated miR-146a state, monocytes and neutrophils no longer produce inflammatory mediators. This phenomenon is referred to as endotoxin-tolerance (14). In the present study, the LPS challenge enhanced miR-146a expression and this result is consistent with previous studies. However, administration of sevoflurane did not alter the expression of miR-146a significantly. A possible explanation of this result is that miR-146a may not be involved in the lung protective mechanisms of sevoflurane. Another explanation is that the statistical differences were not reached due to ‘mixture’ sample of whole lung homogenates, which include monocytes, neutrophils, macrophages, epithelial cells and blood vessels. This means that the miRNA expression profile reflects the sum of these different cells. For this reason, significant differences between groups could not be detected. To clarify the role of miR-146a in the immunomodulatory effect of anesthetic agents, it is important to determine the expression of miR-146a in the various cell types participating in inflammation.

Current knowledge of the organ protective effects of anesthetic agents mainly originates from studies of ischemia-reperfusion injury (15,16). The administration of a volatile anesthetic prior to ischemia, known as preconditioning, has been shown to attenuate ischemia-reperfusion-induced injury in the heart, lung, kidney and liver (17–19). The preconditioning effects of volatile anesthetics were also confirmed in an endotoxin-induced ALI model (20). Although preconditioning appears to be an effective approach, the clinical applicability of this phenomenon is limited, as treatments are usually initiated following the onset of a trigger event. By contrast, postconditioning would be more applicable in a clinical situation. Hofstetter et al (21) examined the postconditioning effect of sevoflurane in an in vivo model of LPS-induced endotoxemia in rats, where administration of sevoflurane 15 min after intravenous injection of LPS resulted in decreased TNF-α and IL-1β. The present study demonstrated that postconditioning is effective even 2 h after LPS stimulation and indicates anesthetic postconditioning could be initiated in a later phase of clinical treatment. However, these lung protective effects were confirmed only during anesthesia and changes of lung function and inflammation following anesthesia remain unknown. Further investigations of temporal changes of miRNA, inflammatory cytokine expression and mortality following anesthesia are required.

The present study has certain limitations. First, individual miRNAs bind to multiple target mRNAs and mRNAs are not regulated by a single miRNA. Further research is required to identify the specific associations between each miRNA and mRNA using antagonists or transgenic animal models. Second, a limited number of mediators associated with the innate immune system by TLR4 were examined. There are a number of other constitutive mediators in the pathways and the association between these mediators and miRNAs requires further investigation.

In conclusion, the present study revealed that the miRNA expression patterns are altered by sevoflurane anesthesia in a rat LPS-induced ALI model. These results suggested that the expression and function of miRNA are involved in the fundamental mechanism of the lung protective effect of volatile anesthetics.

 References RubenfeldGDCaldwellEPeabodyEWeaverJMartinDPNeffMSternEJHudsonLDIncidence and outcomes of acute lung injuryN Engl J Med35316851693200510.1056/NEJMoa05033316236739 VoigtsbergerSLachmannRALeutertACSchläpferMBooyCReyesLUrnerMSchildJSchimmerRCBeck-SchimmerBSevoflurane ameliorates gas exchange and attenuates lung damage in experimental lipopolysaccharide-induced lung injuryAnesthesiology11112381248200910.1097/ALN.0b013e3181bdf85719934867 WinterJJungSKellerSGregoryRIDiederichsSMany roads to maturity: microRNA biogenesis pathways and their regulationNat Cell Biol11228234200910.1038/ncb0309-22819255566 DaiRAhmedSAMicroRNA, a new paradigm for understanding immunoregulation, inflammation and autoimmune diseasesTransl Res157163179201110.1016/j.trsl.2011.01.00721420027 BartelDPMicroRNAs: Target recognition and regulatory functionsCell136215233200910.1016/j.cell.2009.01.00219167326 TanakaSIshikawaMAraiMGendaYSakamotoAChanges in microRNA expression in rat lungs caused by sevoflurane anesthesia: A TaqMan® low-density array studyBiomed Res33255263201210.2220/biomedres.33.25523124245 IshikawaMTanakaSAraiMGendaYSakamotoADifferences in microRNA changes of healthy rat liver between sevoflurane and propofol anesthesiaAnesthesiology11712451252201210.1097/ALN.0b013e318274667623090150 LiewFYXuDBrintEKO'NeillLANegative regulation of toll-like receptor-mediated immune responsesNat Rev Immunol5446458200510.1038/nri163015928677 TaganovKDBoldinMPChangKJBaltimoreDNF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responsesProc Natl Acad Sci USA1031248112486200610.1073/pnas.060529810316885212 BazzoniFRossatoMFabbriMGaudiosiDMiroloMMoriLTamassiaNMantovaniACassatellaMALocatiMInduction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signalsProc Natl Acad Sci USA10652825287200910.1073/pnas.081090910619289835 O'ConnellRMTaganovKDBoldinMPChengGBaltimoreDMicroRNA-155 is induced during the macrophage inflammatory responseProc Natl Acad Sci USA10416041609200710.1073/pnas.061073110417242365 MoschosSAWilliamsAEPerryMMBirrellMABelvisiMGLindsayMAExpression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoidsBMC Genomics8240200710.1186/1471-2164-8-24017640343 TiliEMichailleJJCiminoAModulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shockJ Immunol17950825089200710.4049/jimmunol.179.8.508217911593 NahidMASatohMChanEKMechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signalingJ Immunol18617231734201110.4049/jimmunol.100231121178010 RiessMLStoweDFWarltierDCCardiac pharmacological preconditioning with volatile anesthetics: From bench to bedsideAm J Physiol Heart Circ Physiol286H1603H1607200410.1152/ajpheart.00963.200315072968 TanakaKLudwigLMKerstenJRPagelPSWarltierDCMechanisms of cardioprotection by volatile anestheticsAnesthesiology100707721200410.1097/00000542-200403000-0003515108989 LiuRIshibeYUedaMIsoflurane-sevoflurane adminstration before ischemia attenuates ischemia-reperfusion-induced injury in isolated rat lungsAnesthesiology92833840200010.1097/00000542-200003000-0002710719962 LeeHTOta-SetlikAFuYNasrSHEmalaCWDifferential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivoAnesthesiology10113131324200410.1097/00000542-200412000-0001115564938 Beck-SchimmerBBreitensteinSUrechSDe ConnoEWittlingerMPuhanMJochumWSpahnDRGrafRClavienPAA randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anestheticAnn Surg248909918200810.1097/SLA.0b013e31818f3dda19092335 ReutershanJChangDHayesJKLeyKProtective effects of isoflurane pretreatment in endotoxin-induced lung injuryAnesthesiology104511517200610.1097/00000542-200603000-0001916508399 HofstetterCBoostKAFlondorMBasagan-MogolEBetzCHomannMMuhlHPfeilschifterJZwisslerBAnti-inflammatory effects of sevoflurane and mild hypothermia in endotoxemic ratsActa Anaesthesiol Scand51893899200710.1111/j.1399-6576.2007.01353.x17635397

Anesthetics ameliorate lipopolysaccharide (LPS)-induced increases in inflammatory cytokine gene expression in lung. Evaluation of (A) tumor necrosis factor-α (TNF-α), (B) interleukin-6 (IL-6) and (C) nuclear factor-κB (NF-κB) messenger RNA expression in lung tissue. Data are expressed relative to the normalized mRNA level in the control group. Data are mean ± standard deviation. *P<0.05 vs. control. #P<0.05 vs. LPS.

Effects of 6 h anesthetic treatment on LPS-induced alterations of PaO2, PaCO2 and MAP.

Variables Control LPS LPS-sevo
PaO2 544±34 293±24a 375±26a,b
PaCO2 35.7±4.0 55.3±6.1a 45.2±4.5a,b
MAP 126±5 96±5 93±7

Data are mean±standard deviation in mmHg. Partial arterial oxygen tension (PaCO2) and mean arterial pressure (MAP) were determined in the four study groups at 6 h. Fraction of inspired oxygen (FiO2)=1.0.

P<0.05 vs. control

P<0.05 vs. lipopolysaccharide (LPS) Sevo, sevoflurane.

LPS-responsive miRNAs in lung tissue.

LPS LPS-sevo
Assay Fold change P-value Fold change P-value
let-7a 0.31±0.22 0.002 0.38±0.30 0.007
let-7c 0.51±0.16 0.008 0.48±0.29 0.005
let-7d 0.50±0.20 0.002 0.57±0.17 0.003
let-7i 0.33±0.15 <0.008 0.49±0.27a 0.01
miR-9 2.21±0.91 0.009 2.18±0.82 0.006
miR-125b 0.27±0.13 0.004 0.33±0.14 0.001
miR-127 3.81±2.04 0.001 3.49±1.27 0.001
miR-146a 7.32±2.01 <0.01 8.67±2.27 <0.001
miR-155 19.36±4.47 <0.001 8.01±2.23a <0.001
miR-301a 0.29±0.20 0.004 0.38±0.24 0.006
miR-301b 0.28±0.26 0.005 0.36±0.30 0.006
miR-30e 1.58±0.32 0.009 1.82±0.48 0.008
miR-322 0.58±0.14 0.003 0.45±0.27 0.006
miR-340-5p 2.96±0.61 <0.001 3.26±1.18 0.002
miR-425 2.03±0.36 0.006 1.88±0.28 0.007

miRNAs that were significantly increased or decreased compared to the control (P<0.01). Values are the mean fold change ± standard deviation in each group. P-value, statistical results of Tukey's test.

P<0.01 vs. lipopolysaccharide (LPS). Sevo, sevoflurane.